Escitalopram Oxalate

Spezifikationen

219861-08-2CAS-Nummer

620-544-8EG-Nummer

(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;oxalic acidIUPAC-Name

C22H23FN2O5Chemische Formel

414.4 g/molMolekulargewicht

Escitalopram oxalate; 219861-08-2; DTXSID1046003; Escitalopram (as oxalate); Lu 26-054-0; Citalopram oxalate, (s)-; 5U85DBW7LO; NSC-758934; Lu-26-054-0; LU-26-054-O; DTXCID9026003; Escitslopram; Escitalopram Oral; RefChem:56379; Escitalopram Oral Solution; 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-,(1S)-, ethanedioate(1:1); Lexapro; (S)-Citalopram Oxalate; (S)-(+)Citalopram oxalate; Escitalopram (oxalate); MFCD06407826; (S)-(+)-Citalopram Oxalate; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;oxalic acid; (S)-1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile oxalate; 5-Isobenzofurancarbonitrile,1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-,ethanedioate (1:1); C22H23FN2O5; NCGC00095903-01; S-(+)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate; 5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-, ethanedioate (1:1); S-(+)-5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, oxalate; 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-, ethanedioate (1:1); CAS-219861-08-2; Escitalopram oxalate [USAN]; Gaudium; Entact; Cipra-Pro; Escitalopramoxalate; (S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Oxalate; Escitalopram Oxalate; (S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Ethanedioate; (+)-(S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Oxalate; Lexapro (TN); Escitalopram oxalate CRS; (S)-Escitalopram Oxalate; UNII-5U85DBW7LO; SCHEMBL35123; MLS001401408; SPECTRUM1505216; (+)-(S)-Citalopram oxalate; MLD-55; orb1300720; orb3141384; CHEMBL1200322; SCHEMBL30223023; Escitalopram oxalate (JAN/USP); MSK11176O; (S)-(+ )-Citalopram oxalate; ESCITALOPRAM OXALATE [MI]; Escitalopram oxalate [USAN:USP]; Escitalopram (oxalate) (Standard); ESCITALOPRAM OXALATE [JAN]; GLXC-03026; HMS2051D11; HMS2231M16; HMS3370I17; HMS3393D11; HMS3713D16; HY-14258AR; Pharmakon1600-01505216; ESCITALOPRAM OXALATE [VANDF]; Tox21_111535; CCG-39559; EBC-80071; ESCITALOPRAM OXALATE [MART.]; HB1804; HY-14258A; NSC758934; ESCITALOPRAM OXALATE [USP-RS]; ESCITALOPRAM OXALATE [WHO-DD]; AKOS016340275; Tox21_111535_1; AC-6770; CS-2054; Escitalopram for system suitability CRS; FC20465; KS-1263; NC00194; NSC 758934; SB17454; NCGC00178555-02; (1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Ethanedioate; BC164423; Citalopram S-Isomer; Escitalopram Oxalate; ESCITALOPRAM OXALATE [ORANGE BOOK]; SMR000469191; SY067062; ESCITALOPRAM OXALATE [EP MONOGRAPH]; (S)-Citalopram oxalate - Bio-X trade mark; ESCITALOPRAM OXALATE [USP MONOGRAPH]; E0958; E7209; T6493; D02567; Escitalopram oxalate, >=98% (HPLC), powder; SR-01000763053; SR-01000763053-3; Q27262882; Z3235136057; Escitalopram oxalate, EuropePharmacopoeia (EP) Reference Standard; Escitalopram oxalate, United States Pharmacopeia (USP) Reference Standard; Escitalopram for system suitability, EuropePharmacopoeia (EP) Reference Standard; Escitalopram Oxalate, Pharmaceutical Secondary Standard; Certified Reference Material; (+)-(S)-1-[3-(Dimethylamino)propyl] -1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancar bonitrile oxalate; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile;oxalic acid; Citalopram oxalate, (S)-; 1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran-carbonitrile oxalate; Oxalic acid--(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile (1/1)Synonyme